 |
|
|
|
|
|
|
|
 |
Results for 'Drug Delivery in Cancer' |
|
|
| Title |
 |
Publication Date |
|
Price |
|
Relevance |
 |
|
|
|
|
Drug Delivery in Cancer
Technologies, Markets and Companies
|
September 2008 |
£2020 |
100 % |
Drug Delivery Markets, Vol II
Implantable Injectable
|
February 2007 |
£1680 |
35 % |
Baxter International Medical Device Company Intelligence Report
|
October 2005 |
£295 |
30.5 % |
Nano Drug Delivery - The Impact of Nanotechnology in Drug Delivery
Global Developments, Market Analysis and Future Prospects
|
March 2005 |
£1140 |
30.45 % |
Drug Delivery Markets
Oral Delivery
|
January 2007 |
£1680 |
29.4 % |
The Commercial Success of Cancer Therapeutic Antibodies
The Formation of a Second Wave
|
November 2005 |
£1655 |
29.05 % |
Advanced Drug Formulation Design to Optimize Therapeutic Outcomes
|
September 2007 |
£115 |
28.5 % |
Global Cancer Treatment Forecast to 2012
|
August 2008 |
£535 |
27.65 % |
Competitive Outlook on Non-Antibody Based Cancer Vaccines
|
August 2006 |
£1655 |
27.65 % |
Currently Druggable in Prostate Cancer
A Drug Target Competitive Analysis
|
September 2008 |
£1310 |
27.65 % |
Currently Druggable in Breast Cancer: A Drug Target Competitive Analysis
|
August 2008 |
£1310 |
27.65 % |
Chronotherapeutics
|
September 2003 |
£75 |
27.65 % |
Innovations in Cancer
Novel Therapeutics, New Diagnostics and Future R&D Strategies
|
February 2007 |
£1495 |
27.65 % |
Cell Therapy
Technologies, Markets and Companies
|
September 2008 |
£3030 |
26 % |
Advanced Drug Delivery Systems: Probing the Route to Growth
New Developments, New Technologies, Companies and Trends
|
October 2001 |
£960 |
25.9 % |
Drug Delivery Systems
US Market Outlook, Advances for Pharma, Biotech & Medical Devices
|
September 2006 |
£1545 |
25.55 % |
Pipeline Insight: Insulin Antidiabetics
Return to Injections Alternative Delivery Methods Fall by The Wayside
|
July 2008 |
£6000 |
25.5 % |
Innovation in Drug Delivery
The future of nanotechnology and non-invasive protein delivery
|
November 2006 |
£1495 |
25.2 % |
Beyond the Blockbuster Drug
Strategies for nichebuster drugs, targeted therapies and personalized medicine.
|
February 2005 |
£1495 |
25.2 % |
Oncology Market Forecast to 2013
|
July 2008 |
£10975 |
24.5 % |
The Bourne Report – Medical Device Quarterly
|
March 2008 |
£2625 |
23.8 % |
The Deployment of Antibody Technologies for the Advancement of Cancer Therapeutics
|
April 2008 |
£1525 |
22.75 % |
Drug Delivery Series I-IV
|
April 2007 |
£4810 |
22.75 % |
Biotechnology and Biopharmaceuticals
Transforming Proteins and Genes into Drugs
|
July 2003 |
£55.95 |
22.75 % |
Outlook for RNAi, 2007
siRNA and miRNA in biology, diagnostics and therapeutics
|
June 2007 |
£1495 |
22.5 % |
Triple Analysis: Apoptosis Agents, Antibodies and Vaccines in Oncology
|
December 2006 |
£2930 |
22.4 % |
Transdermal Drug Delivery
Technologies, Markets, and Companies
|
September 2008 |
£1685 |
22.4 % |
Oncology Brand Commercialization
Resource Allocation
|
May 2005 |
£2220 |
22.05 % |
Nanotechnology in Health Care to 2009
|
May 2005 |
£2830 |
22.05 % |
Drug Delivery Technology: Revolutionizing CNS Therapies
|
December 2007 |
£945 |
21.35 % |
NeoPharm, Inc. - SWOT Analysis
|
October 2008 |
£66 |
19 % |
Decoding Big Pharmas R&D Strategy in Oncology
|
September 2007 |
£3125 |
18.9 % |
Decoding Big Pharma's R&D Strategy in Oncology
|
September 2007 |
£1415 |
18.9 % |
Decoding Big Pharma's R&D Strategy in Oncology
|
September 2007 |
£1415 |
18.9 % |
Decoding Big Pharma's R&D Strategy in Oncology
|
September 2007 |
£1415 |
18.9 % |
Decoding Big Pharma's R&D Strategy in Oncology
|
September 2007 |
£1415 |
18.9 % |
Scrip Yearbook 2007
23rd Edition (2 Volumes)
|
January 2006 |
£895 |
18.55 % |
RNAi Therapeutics 2008
|
November 2007 |
£2350 |
18.55 % |
The Future of Targeted Therapeutics
Key Technologies, New Therapy Area Applications and Leading Players
|
March 2008 |
£1995 |
18.55 % |
Nanotechnology
Revolutionizing R&D to Develop Smarter Therapeutics and Diagnostics
|
January 2008 |
£1995 |
18.2 % |
The Exploding RNAi Market & Future Direction
Translating the Genome into a Large Market by 2009
|
February 2001 |
£960 |
17.85 % |
Triple Progress Analysis: Lymphoma Therapeutics, Protein Kinase Inhibitors & Therapeutic Antibodies
|
May 2006 |
£2930 |
17.85 % |
Triple Analysis: Protein Kinase Inhibitors, Antibodies and Vaccines in Oncology
|
August 2006 |
£2930 |
17.5 % |
Cancer Therapeutics
Market Insight and R&D Pipeline Analysis
|
August 2008 |
£1460 |
17.5 % |
Burger's Medicinal Chemistry and Drug Discovery
6 Volume Set
|
March 2003 |
£1331 |
17.15 % |
Triple Analysis: Melanoma Therapeutics, Antibodies and Vaccines in Oncology
|
August 2006 |
£2930 |
17.15 % |
RNA Interference for Drug R&D
Applications, Alliances, Companies and WW Market to 2011
|
July 2007 |
£1745 |
16.8 % |
Pancreatic Cancer: Industry Background Report
List of Companies
|
October 2005 |
£235 |
16.5 % |
Colorectal Cancer: Industry Background Report
List of Companies
|
October 2005 |
£295 |
16.5 % |
Lung cancer: Industry Background Report
List of Companies
|
October 2005 |
£295 |
16.5 % |
Breast Cancer: Industry Background Report
List of Companies
|
October 2005 |
£345 |
16.5 % |
Liver Cancer: Industry Background Report
List of Companies
|
October 2005 |
£235 |
16.5 % |
Prostate Cancer: Industry Background Report
List of Companies
|
October 2005 |
£345 |
16.5 % |
Pipeline Insight: Nociceptive Pain
Safety Profile Uppermost in Crowded Market
|
October 2004 |
£6000 |
16.45 % |
Research & Development in the Pharmaceutical Industry
Options for success
|
February 2004 |
£825 |
16.45 % |
Drug Delivery Technology: Developing a New Generation of Vaccines
|
November 2007 |
£945 |
16.45 % |
Monoclonal Antibodies 2007
Competitive Landscape & Pipeline Insight
|
January 2007 |
£1515 |
16.1 % |
Drug Targets for Breast Cancer
|
January 2006 |
£1095 |
16 % |
Gene Therapy
Technologies, Markets and Companies
|
September 2008 |
£1440 |
16 % |
Pipeline Insight: Cancer Vaccines and Cell Therapies
Technical Know How Needs Translation Into Clinical and Commercial Rewards
|
April 2005 |
£6000 |
15.75 % |
Targeted Therapies in Oncology
A World Review
|
December 2006 |
£4205 |
15.75 % |
Emerging Opportunities in Cancer Nanomedicine
|
August 2006 |
£995 |
15.75 % |
New Concepts in Cancer Therapeutics
|
December 2005 |
£2080 |
15.4 % |
Market for Bioengineered Protein Drugs; The
|
January 2007 |
£3265 |
15.4 % |
Drug Delivery Technologies: Players, products & prospects to 2015
|
November 2007 |
£1795 |
15.4 % |
Pipeline Insight: Breakthrough Pain
Fast-acting players will capture majority market share
|
November 2006 |
£6000 |
15.4 % |
RNAi
Technologies, Markets and Companies
|
September 2008 |
£2020 |
15.05 % |
Commercial and Pipeline Insight: Opioids
Short Acting and Anti-Abuse Technologies Set to Fragment and Grow The Market
|
March 2008 |
£7600 |
15.05 % |
Nanotechnology in Health Care
|
February 2007 |
£3030 |
15 % |
Generic Drug Market in Canada
|
February 2008 |
£945 |
14.7 % |
Immunomodulators
Therapeutic Needs, Pipelines & Prospects
|
August 2007 |
£1495 |
14.35 % |
Drug Delivery in Central Nervous System Diseases
technologies,markets and companies
|
September 2008 |
£900 |
14 % |
Next Generation Protein Engineering and Drug Design
Strategies to boost efficacy and improve drug delivery
|
February 2007 |
£1495 |
13.65 % |
Stakeholder Opinions
Novel Therapeutic Approaches in Cardiovascular Medicine - Lack of Market Prospects for Biologics Expose An Opportunity for Cell and Gene Therapies
|
July 2008 |
£3800 |
13.65 % |
Chemotherapy Market Insights, 2006-2016
A Critical Analysis of Cancer Research, Treatments, Pipelines, and Commercial Opportunities
|
April 2006 |
£1900 |
13.65 % |
Medical Nanotechnology Markets
|
September 2008 |
£2290 |
13.3 % |
EU Pharma IMPACTS
|
August 2005 |
£450 |
12.95 % |
Future of RNAi Therapeutics, The
Drug Pipelines and Prospects
|
September 2008 |
£1995 |
12.95 % |
Top Companies and Products in the RNA/DNA Therapy Products Market Forecasts:
The Challenge Of Turning Technology Into Therapy
|
July 2007 |
£1999 |
12.6 % |
Medical Imaging Markets, Volume V
Molecular Imaging
|
May 2007 |
£2015 |
12.6 % |
Preclinical Cancer Therapeutics 2007
Decoding Next Generation Drug Targets for Market Success
|
December 2006 |
£1600 |
12.6 % |
The Outlook For RNAi
Accelerating drug discovery and the development of RNAi therapeutics
|
January 2005 |
£1495 |
12.6 % |
Stakeholder Opinions: Primary Brain Cancer
Temozolomide Turns Heads
|
July 2007 |
£2005 |
12.6 % |
Modern Biopharmaceuticals
Design, Development and Optimization, 4 Volumes
|
September 2005 |
£440 |
12.6 % |
Stakeholder Insight: Pricing and Reimbursement in Oncology
Do payers believe oncology drugs offer good value?
|
December 2006 |
£6000 |
12.25 % |
Cancer Cell Therapy Markets
|
March 2008 |
£2290 |
12.25 % |
Global Protein Therapeutics Market Analysis
|
September 2007 |
£1210 |
11.9 % |
Italy Drug Delivery Devices Investment Opportunities, Analysis and Forecasts to 2012
|
May 2008 |
£2020 |
11.9 % |
Spain Drug Delivery Devices Investment Opportunities, Analysis and Forecasts to 2012
|
May 2008 |
£2020 |
11.9 % |
UK Drug Delivery Devices Investment Opportunities, Analysis and Forecasts to 2012
|
May 2008 |
£2020 |
11.9 % |
Japan Drug Delivery Devices Investment Opportunities, Analysis and Forecasts to 2012
|
May 2008 |
£2020 |
11.55 % |
South Africa Drug Delivery Devices Investment Opportunities, Analysis and Forecasts to 2012
|
May 2008 |
£2020 |
11.55 % |
Pipeline Insight: Cancer Overview
Increasing Diversity Offers Both High Risk And Reward
|
September 2007 |
£7600 |
11.55 % |
Brazil Drug Delivery Devices Investment Opportunities, Analysis and Forecasts to 2012
|
May 2008 |
£2020 |
11.55 % |
China Drug Delivery Devices Investment Opportunities, Analysis and Forecasts to 2012
|
May 2008 |
£2020 |
11.2 % |
RNA Interference Markets
|
September 2008 |
£1345 |
11.2 % |
Pain Therapeutics
Drugs, Markets and Companies
|
September 2008 |
£1080 |
10.85 % |
Australia Drug Delivery Devices Investment Opportunities, Analysis and Forecasts to 2012
|
May 2008 |
£2020 |
10.85 % |
Netherlands Drug Delivery Devices Investment Opportunities, Analysis and Forecasts to 2012
|
May 2008 |
£2020 |
10.85 % |
The Global Pain Therapeutics Market
Market Analysis, R&D Pipelines and Competitive Landscape
|
October 2007 |
£1020 |
10.85 % |
Commercial Insight: Pain Market Overview
Non-Traditional Analgesics and Opioid Reformulations to Sustain Sector Growth
|
October 2008 |
£8000 |
10.5 % |
Pain Therapeutics 2005
Market Dynamics and Outlook
|
May 2005 |
£1345 |
10.15 % |
Global Protein Therapeutics Market, The
Market Dynamics and Pipeline Analysis
|
December 2006 |
£2020 |
10.15 % |
Italy Drug Delivery Devices Investment Opportunities, Analysis and Forecasts to 2012
|
May 2008 |
£1020 |
10.15 % |
Japan Drug Delivery Devices Investment Opportunities, Analysis and Forecasts to 2012
|
May 2008 |
£1020 |
9.8 % |
UK Drug Delivery Devices Investment Opportunities, Analysis and Forecasts to 2012
|
May 2008 |
£1020 |
9.8 % |
United States Drug Delivery Devices Medical Equipment Industry Report
Detailed Analysis of the Medical Equipment & Medical Devices Market Covering Infusion Systems, Inhalation Systems and Needle Free Injections Medical Equipment and Supplies
|
April 2008 |
£1020 |
9.8 % |
The World Market for Gynaecology
2007-2017
|
September 2007 |
£3200 |
9.8 % |
Drug Discovery
Current trends and future prospects
|
February 2001 |
£300 |
9.8 % |
South Africa Drug Delivery Devices Investment Opportunities, Analysis and Forecasts to 2012
|
May 2008 |
£1020 |
9.45 % |
Biomarkers
The Expanding Global Market
|
November 2007 |
£1625 |
9.45 % |
Cell Therapy Markets
|
July 2007 |
£2290 |
9.45 % |
Therapeutic Proteins
|
February 2005 |
£1999 |
9.45 % |
Brazil Drug Delivery Devices Investment Opportunities, Analysis and Forecasts to 2012
|
May 2008 |
£1020 |
9.45 % |
The Pharmaceutical Market Outlook to 2015
Implementing innovative, long-term strategies for sustainable future growth
|
January 2005 |
£1495 |
9.1 % |
Netherlands Drug Delivery Devices Investment Opportunities, Analysis and Forecasts to 2012
|
May 2008 |
£1020 |
9.1 % |
Antiviral Therapeutics
Technologies, Markets and Companies
|
September 2008 |
£1885 |
8.75 % |
Rimonabant: The first of the Cannabinoid blockbusters
|
June 2007 |
£1499 |
8.75 % |
Nitric Oxide
Therapeutics, Markets and Companies
|
September 2008 |
£1010 |
8.75 % |
Global Vaccines Market 2008-2023, The
|
August 2008 |
£1499 |
8.75 % |
Australia Drug Delivery Devices Investment Opportunities, Analysis and Forecasts to 2012
|
May 2008 |
£1020 |
8.75 % |
Nanomedicine 2006-2011
|
June 2006 |
£1499 |
8.4 % |
Personalized Medicine
scientific & commercial aspects
|
September 2008 |
£2695 |
8.4 % |
Pharmaceutical Pricing: global perspectives
|
September 2004 |
£625 |
8.05 % |
Commercial and Pipeline Insight: HRT for Menopausal Symptoms
A new class restores an old market
|
April 2008 |
£8000 |
8.05 % |
Angiogenesis Modulators
|
January 2008 |
£1885 |
7.7 % |
Cannabinoids
A Potential Blockbuster
|
February 2005 |
£1499 |
7.7 % |
Clinical Trials Business; The
|
August 2006 |
£3265 |
7.35 % |
Animal Biotechnology
Technologies, Markets and Companies
|
September 2008 |
£900 |
7 % |
Executive Guide to Molecular Imaging; The
|
April 2005 |
£395 |
7 % |
Neurodegenerative Disease Drug Market Analysis and Forecasts 2007
|
June 2007 |
£1999 |
6.3 % |
The Executive Guide to Molecular Imaging
|
July 2007 |
£595 |
5.95 % |
Key Diagnostic Testing Markets
|
December 2004 |
£1345 |
5.95 % |
Women's Reproductive Disorders Therapeutics 2008-2018
|
September 2008 |
£1499 |
5.25 % |
Antiageing and Life Enhancement Pharmacotherapeutics
|
January 2006 |
£4600 |
5.25 % |
Partneringreview 2006 – Industry Sector
Volume 6
|
February 2006 |
£1395 |
4.5 % |
Protein Therapeutics Market; The
The Science and Business of a Growing Sector
|
June 2006 |
£2625 |
3.85 % |
|
|
|
|
